Q2 2026 results - Tuesday, July 21, 2026
Press release: English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB)
Interim financial report (PDF 0.5 MB)
Download the interactive presentation (PDF 5.4 MB)
Download the podcast (MP3 33 MB)
Novartis Q2 2026 impact and sustainability update (PDF 1.2 MB)
| Key figures1 | Q2 2026 (USD m) | Q2 2025 (USD m) | % change (USD/cc) |
|---|---|---|---|
| Net sales | 14,408 | 14,054 | 3 (cc: 1) |
| Operating income | 4,750 | 4,864 | -2 (cc: -3) |
| Net income | 3,257 | 4,024 | -19 (cc: -19) |
| EPS (USD) | 1.71 | 2.07 | -17 (cc: -18) |
| Free cash flow | 5,561 | 6,333 | -12 |
Core | |||
| Operating income | 5,940 | 5,925 | 0 (cc: 0) |
| Net income | 4,578 | 4,710 | -3 (cc: -4) |
| EPS (USD) | 2.41 | 2.42 | 0 (cc: -1) |
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 43 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.